Shanghai

Boehringer Ingelheim has been active in China since 1994. Since then, the company has grown extensively in this country, with currently 4,000 employees working in China. Among other offices and facilities in various Chinese cities, Shanghai stands out due to its strategic role for the company. It is the seat of the headquarters of Boehringer Ingelheim in China, and all three business areas (Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing) operate in the metropolis.

Zhangjiang Plant

The Zhangjiang Plant plays a significant role in Human Pharma Global Supply. This site exports products to more than seven Asia-Pacific regions. The products are involved in areas like Stroke, Diabetes, Cardiovascular, Respiratory, Oncology, Immunology and the Central Nervous System (CNS).

Animal Health Global Innovation

Initially put into operation in Shanghai’s Zhangjiang Science City in March 2012, this facility has been dedicated to the R&D of vaccine for livestock. The newly integrated innovation center was inaugurated in 2018 and is currently the largest integrated Animal Health R&D center in China in terms of investment value.

The Biopharmaceuticals Manufacturing Site in Shanghai (Oasis)

The facility is the company’s door to China for its biopharmaceutical contract manufacturing business and was officially put into operation in 2017. As the first and only biopharma manufacturing site in line with global standards set by a multinational pharma company in China, the facility has become a major cornerstone in the company’s strategic blueprint for its global cell culture biopharma business.